Pediatric prophylaxis guidance sharpens antibacterial and antifungal choices in cancer care
The 2026 update of the Pediatric Oncology Group of Ontario clinical practice guideline brings systemic antibacterial and antifungal prophylaxis into a single, harmonized framework for children with cancer and hematopoietic cell transplant recipients. The document centers on two clinical realities that dominate pediatric oncology wards: profound treatment-related neutropenia and the narrow window in which antimicrobial prevention can lower infection risk before an invasive pathogen gains traction.
Across the updated evidence base, investigators identified 13 new randomized trials published since 2019, eight addressing antibacterial prophylaxis and five addressing antifungal prophylaxis, bringing the total body of randomized evidence to 195 trials. That expanded evidence pool did not overturn the central recommendations, but it did sharpen the boundaries of where prophylaxis belongs and where uncertainty is large enough to justify restraint.
Levofloxacin remains the preferred antibacterial option when prophylaxis is chosen
The panel kept a conditional recommendation to consider antibacterial prophylaxis in pediatric patients with acute myeloid leukemia and in those with relapsed acute lymphoblastic leukemia. Those are the settings in which treatment intensity, prolonged neutropenia, and mucosal injury combine to create a high-risk environment for bloodstream infection. In practical terms, antibacterial prophylaxis is meant to suppress the bacterial burden during the most vulnerable phase, before febrile neutropenia becomes a life-threatening emergency.
A strong recommendation to use levofloxacin when antibacterial prophylaxis is planned also remained in place. Fluoroquinolone prophylaxis is attractive because it offers broad gram-negative coverage and a familiar oral route, a combination that can matter in pediatric oncology units where admissions, central venous access, and chemotherapy-induced mucosal disruption create multiple portals for bacteremia.
A new conditional recommendation now addresses a difficult bedside scenario: children who cannot receive levofloxacin. In that group, the panel supports considering no antibacterial prophylaxis rather than forcing an alternative regimen with less certain benefit or greater toxicity. This is a clinically consequential shift because it acknowledges that prophylaxis is not a binary exercise in which any antimicrobial is automatically better than none. The choice has to be anchored in the expected pathogen spectrum, the child’s treatment phase, and the likelihood that a substitute drug will do more harm than good.
Antifungal prevention stays focused on AML and allogeneic transplant recipients
For fungal disease, the update maintains strong recommendations to use antifungal prophylaxis in pediatric patients with acute myeloid leukemia and in allogeneic hematopoietic cell transplant recipients. Those populations remain the clearest candidates because invasive fungal infection thrives in the same biologic territory as prolonged neutropenia, mucosal barrier injury, and immune reconstitution failure. Invasive mold disease is especially dangerous in this setting, where delayed recognition can quickly translate into pulmonary or disseminated infection.
When antifungal prophylaxis is planned, the guideline continues to recommend either an echinocandin or a mold-active azole. The distinction between those options is not cosmetic. Mold-active azoles can offer broader coverage against organisms such as Aspergillus species, while echinocandins provide a different pharmacologic profile and may be preferred when drug interactions or tolerability issues complicate azole use. In pediatric oncology, the drug choice often hinges less on theoretical spectrum alone than on the interaction between antifungal pharmacology and the rest of the treatment plan.
Drug interactions and surveillance now sit beside the prophylaxis decision
Three new good practice statements broaden the practical scope of the guideline. One addresses drug interactions, which are especially relevant in children receiving multi-agent chemotherapy, calcineurin inhibitors after transplant, antiemetics, and supportive medications that can all compete for metabolic pathways. Another reinforces infection prevention practices, and the third calls for ongoing monitoring of infection epidemiology.
Those additions matter because prophylaxis only works inside a larger infection-control strategy. Antibiotic selection can shift the local ecology of resistant organisms; antifungal selection can shift the balance between prophylaxis and breakthrough infection; and transplant or leukemia care units can see their pathogen patterns change over time. A regimen that fits one center’s resistance profile may fit poorly in another if surveillance data are stale.
The update also preserves the use of the Grading of Recommendations Assessment, Development and Evaluation framework, with an international multidisciplinary panel revising and formulating recommendations and classifying evidence quality. That structure gives the guideline its practical value: it does not simply list agents, but ranks confidence and separates strong recommendations from conditional ones. In pediatrics, where trial enrollment is often difficult and patient subgroups are small, this kind of graded guidance is essential for avoiding overgeneralization from adult oncology data.
Why these recommendations remain narrow rather than universal
The guideline does not argue for blanket prophylaxis across all pediatric cancers or all transplant settings. Instead, it keeps the emphasis on selected high-risk groups where the expected benefit is most plausible and the downside can be monitored. Broad antimicrobial exposure carries familiar costs: adverse drug reactions, selection pressure for resistant bacteria, fungal breakthrough under incomplete coverage, and the possibility that a prophylactic strategy obscures evolving local epidemiology until a cluster of infections appears.
The updated evidence base is larger than before, yet the new trials did not create a mandate to widen prophylaxis indiscriminately. They instead support a more precise approach in which AML, relapsed ALL, and allogeneic HCT remain the clearest anchors for use, while levofloxacin, echinocandins, and mold-active azoles retain their central place when prophylaxis is selected.
Future research needs to do what current evidence still cannot: separate pediatric subgroups by disease biology, transplant context, local resistance patterns, and drug interaction burden, then determine which children gain the most from systemic prophylaxis and which can safely avoid it. The next useful trial will not ask whether prophylaxis works in the abstract. It will ask which child, at which point in therapy, with which competing risks, benefits from it most.